Table 7.

Back-transformed LS means PCV2 SERELISA values by treatment and study day for studies B and C

Study	Treatment Group (T)	Day of Study
		− 1	21	24	28 or 29	31	35	38	42
B	T01	0.809	0.884	0.839	0.882	0.842	0.598	0.605	0.560
B	T02	0.808	0.852	0.804	0.478*	0.357*	0.203*	0.196*	0.158*
B	T03	0.805	0.733*	0.722*	0.329*	0.290*	0.186*	0.160*	0.130*
C	T01	0.844	0.877	ND	ND	ND	ND	ND	0.479
C	T02	0.867	0.784*	ND	ND	ND	ND	ND	0.202**
C	T03	0.862	0.709*	ND	ND	ND	ND	ND	0.136**

Value is significantly different from T01 saline controls (*P ≤ 0.0013, ** P ≤ 0.05) within the column (Day of Study; Study Day 0 corresponded to the day of vaccination). All values on Days − 1 and 21 are considered negative based on the assay positive/negative cut-off. SERELISA: the lower the S/Nc SERELISA value the more positive the value is and the higher the antibody level.

ND: not determined.